
Sign up to save your podcasts
Or
Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
3.8
372372 ratings
Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses how Treasuries might react to a government shutdown on Friday. Michael Shah, Pharma Analyst with Bloomberg Intelligence, joins to discuss Novo Nordisk, Ozempic, and the weight loss drug push. Jake Saper, Emergence Capital General Partner, joins to talk about investment strategies, tech, and markets. Jereme Sylvain, CFO at DexCom (NASDAQ: DXCM), joins to discuss company earnings, its initiatives in healthcare and specifically for diabetes, and outlook for the firm and industry. Hosted by Paul Sweeney and Matt Miller.
See omnystudio.com/listener for privacy information.
1,200 Listeners
431 Listeners
2,174 Listeners
992 Listeners
1,795 Listeners
966 Listeners
196 Listeners
1,029 Listeners
181 Listeners
1,267 Listeners
65 Listeners
80 Listeners
31 Listeners
62 Listeners
2 Listeners
55 Listeners
2 Listeners
50 Listeners
7 Listeners
198 Listeners
12 Listeners
232 Listeners
54 Listeners
70 Listeners
17 Listeners
54 Listeners
85 Listeners
371 Listeners
47 Listeners